Parathyroid Hormone-Related Protein Dynamics in Cancer and Bone Physiology

Parathyroid hormone-related protein (PTHrP) is a multifunctional peptide that orchestrates a spectrum of physiological and pathological processes through endocrine, paracrine and intracrine modes of action. In normal bone physiology, PTHrP regulates calcium homeostasis and osteoblast–osteoclast coupling, contributing to bone remodelling and development. In malignancy, aberrant PTHrP expression drives tumour-induced osteolysis, facilitates metastatic colonisation of the skeleton and modulates tumour cell dormancy. The protein’s N-terminal region engages the PTH1 receptor (PTH1R) to activate cAMP-dependent signalling, while its mid- and C-terminal domains exert intracrine influences on cell cycle regulators and transcription factors. The interplay between PTHrP and the bone microenvironment establishes a vicious cycle in which cancer cells and stromal elements reciprocally enhance osteolysis and tumour growth. Recent advances have illuminated the dualistic nature of PTHrP, revealing contexts in which it may suppress early tumour progression yet promote late-stage metastasis. A nuanced understanding of PTHrP dynamics offers prospects for novel biomarker discovery and targeted interventions aimed at mitigating skeletal complications of cancer and harnessing anabolic pathways in osteoporosis treatment.

Research from Nature Portfolio

Investigations into head and neck squamous cell carcinoma have identified Parathyroid Hormone-Like Hormone (PTHLH) as an independent marker of poor prognosis. This work demonstrated that PTHLH is transcriptionally regulated by the Runt-related transcription factor RUNX2, forming a calcium-sensitive positive-feedback loop that amplifies tumour growth. Elevated PTHLH levels were shown to stimulate proliferation via up-regulation of key cell-cycle mediators including CCNA2, CCNE2 and CDC25A, and to raise systemic calcium, further reinforcing RUNX2 activity. The elucidation of the RUNX2–PTHLH axis underscores PTHrP’s autocrine/paracrine role in driving aggressive tumour phenotypes and highlights a potential therapeutic nexus for disrupting this feed-forward circuit.

Parathyroid Hormone-Related Protein Dynamics in Cancer and Bone Physiology publication trend

The graph below shows the total number of articles in parathyroid hormone-related protein dynamics in cancer and bone physiology across all publications each year (not limited to Nature Index journals).

Technical terms

PTHrP (Parathyroid Hormone-Related Protein): A peptide hormone involved in calcium regulation, bone remodelling and tumour progression through endocrine, paracrine and intracrine actions.

PTH1R (Parathyroid Hormone 1 Receptor): A G-protein-coupled receptor that binds PTH and PTHrP, activating intracellular cAMP signalling to regulate bone cell function.

Paracrine signalling: Local communication in which a cell secretes factors that act on neighbouring cells.

Intracrine action: A mechanism whereby a protein exerts its effects within the cell of origin, often via nuclear or cytoplasmic interactions.

Osteolysis: The pathological destruction of bone tissue, often driven by tumour-secreted factors that stimulate osteoclast activity.

Metastatic niche: The specialised microenvironment within distant tissues that supports the survival, dormancy or outgrowth of disseminated tumour cells.

References

1. Parathyroid Hormone-Like Hormone is a Poor Prognosis Marker of Head and Neck Cancer and Promotes Cell Growth via RUNX2 Regulation. Scientific Reports (2017).
2. Parathyroid hormone receptor (PTH1R) signaling mediates breast cancer metastasis to bone in mice. JCI Insight (2023).
3. PTHrP intracrine actions divergently influence breast cancer growth through p27 and LIFR. Breast Cancer Research (2024).
4. Parathyroid Hormone-Related Protein/Parathyroid Hormone Receptor 1 Signaling in Cancer and Metastasis. Cancers (2023).
5. From Good to Bad: The Opposing Effects of PTHrP on Tumor Growth, Dormancy, and Metastasis Throughout Cancer Progression. Frontiers in Oncology (2021).